Amphastar Pharmaceuticals, Inc.
$28.25+$0.14 (+0.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $824.5M
- P/E
- 8.4x
- EV / EBITDA
- 6.2x
- Revenue
- $719.9M
- Net margin
- 13.6%
- ROCE
- 9.5%
Price chart
Technical chartScreen technicals →+11.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +8.9%
- 3M
- +30.3%
- 6M
- +56.3%
- 1Y
- +11.4%
- 5Y
- +37.7%
52-week range
Day change +$0.14 (+0.5%) from $28 to $28 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AMPH, bought on each weekday since 2021.
News & filings
What Amphastar Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOperating margin fell for three years, from 30.6% to 19.5%.
Strengths (1)
- Free cash flow in fiscal 2025 equals 14.4% of the company's market value.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Read moreShow less
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Sector
- Healthcare
- Shares outstanding
- 46.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $824.5M
- P/E
- 8.4x
- P/B
- 1.0x
- EV / EBITDA
- 6.2x
- EV / Sales
- 1.8x
- P/S
- 1.1x
- 52-week high
- $29.71
- 52-week low
- $16.87
Profitability
- Operating margin
- 19.5%
- Net margin
- 13.6%
- EBITDA margin
- 29.5%
- ROE
- 12.4%
- ROCE
- 9.5%
- ROA
- 6.0%
- Asset turnover
- 0.44
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $719.9M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 13.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -38.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $119.0M
Solvency
- Current ratio
- 4.02
- Debt / Equity
- 0.83
- Debt / Assets
- 0.40
- CFO / Net profit
- 1.59
- Cash / Market cap
- 20.6%
Where the revenue went
Of every $100 of FY2025 revenue, $14 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $363.8M |
| Revenue | Gross profit | $356.1M |
| Gross profit | Research and development | $85.8M |
| Gross profit | Selling, general and administrative | $129.8M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $140.4M |
| Operating income | Pretax income | $123.6M |
| Operating income | Interest and other expense | $16.8M |
| Pretax income | Tax and other | $25.5M |
| Pretax income | Net income | $98.1M |
Revenue and net profit
Revenue fell 1.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $499.0M | $91.4M |
| FY2023 | $644.4M | $137.5M |
| FY2024 | $732.0M | $159.5M |
| FY2025 | $719.9M | $98.1M |
Cash flows
FY2025: $156.1M from operations, $119.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $89.2M | $65.1M |
| FY2023 | $183.5M | $145.3M |
| FY2024 | $213.4M | $172.3M |
| FY2025 | $156.1M | $119.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $719.9M-1.7%1Y
- EBITDA
- $212.3M-23.4%1Y
- Net profit
- $98.1M-38.5%1Y
- Cash from operations
- $156.1M-26.8%1Y
- Free cash flow
- $119.0M-31.0%1Y
- Revenue CAGR, 3Y
- 13.0%
- Net profit CAGR, 3Y
- 2.4%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $719.9M | $212.3M | $98.1M | $119.0M | 12.4% | -1.7% | -38.5% |
Monthly returns
Month-by-month returns of AMPH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.6B |
| Current assets | $636.0M |
| Non-current assets | $993.3M |
| Liabilities | $840.5M |
| Current liabilities | $158.2M |
| Non-current liabilities | $682.3M |
| Equity | $788.8M |
| Paid-in capital | $535.4M |
| Retained earnings | $666.9M |
| Treasury stock | $408.1M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AMPH highlighted.
P/E against peers
AMPH trades at 8.4x earnings against a peer median of -6.4x.
Not shown (no positive earnings and no EV / Sales): ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc., Replimune Group, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc.AMPHthis company | $824.5M | 8.4x | 1.0x | 12.4% | 6.2x |
| Theravance Biopharma, Inc.TBPH | $843.9M | 8.0x | 2.8x | 35.7% | 5.3x |
| Janux Therapeutics, Inc.JANX | $839.1M | -7.4x | 0.9x | -11.9% | -5.2x |
| ORIC Pharmaceuticals, Inc.ORIC | $830.2M | -6.4x | 2.2x | -33.7% | -5.6x |
| LB Pharmaceuticals IncLBRX | $828.8M | -32.9x | 2.8x | -8.4% | -19.4x |
| Sana Biotechnology, Inc.SANA | $823.7M | -3.4x | 5.1x | -151.8% | -4.3x |
| Replimune Group, Inc.REPL | $815.0M | -3.3x | 2.0x | -59.5% | -3.3x |
| Esperion Therapeutics, Inc.ESPR | $805.8M | — | — | 7.5% | 13.9x |
| Lumexa Imaging Holdings, Inc.LMRI | $791.7M | -16.8x | 1.4x | -8.0% | 12.0x |
| Peer median | — | -6.4x | 2.2x | -10.1% | -3.8x |
Year-to-date ROI
AMPH since 1 January, against earlier years.
Historical volatility
AMPH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 21.5% |
| FY2023 | 30.6% |
| FY2024 | 28.1% |
| FY2025 | 19.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $719.9M |
| Cost of revenueCost Of Revenue | $363.8M |
| Gross profitGross Profit | $356.1M |
| Operating expensesOperating Expense | $215.7M |
| Research and developmentResearch And Development | $85.8M |
| Selling, general and administrativeSelling General And Administration | $129.8M |
| Total expensesTotal Expenses | $579.5M |
| Operating incomeOperating Income | $140.4M |
| Interest and other | |
| Pretax incomePretax Income | $123.6M |
| TaxTax Provision | $25.5M |
| Net incomeNet Income | $98.1M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.6B |
| Current assetsCurrent Assets | $636.0M |
| Non-current assetsTotal Non Current Assets | $993.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $840.5M |
| Current liabilitiesCurrent Liabilities | $158.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $682.3M |
| EquityTotal Equity Gross Minority Interest | $788.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $156.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $156.1M |
| Net income, continuing operationsNet Income From Continuing Operations | $98.1M |
| Depreciation and amortisationDepreciation And Amortization | $63.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $63.2M |
| Depreciation | $38.1M |
| Amortization cash flowAmortization Cash Flow | $25.1M |
| Amortization of intangiblesAmortization Of Intangibles | $25.1M |
| Stock-based compensationStock Based Compensation | $27.3M |
| Deferred taxDeferred Tax | $27.6M |
| Deferred income taxDeferred Income Tax | $27.6M |
| Operating gains and lossesOperating Gains Losses | $2.5M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $2.5M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $0.00 |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Change in working capitalChange In Working Capital | -$66.0M |
| Other non-cash itemsOther Non Cash Items | $3.4M |
| Investing cash flowInvesting Cash Flow | -$70.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$70.3M |
| Capital expenditureCapital Expenditure | -$37.1M |
| Purchase of PP&EPurchase Of PPE | -$34.9M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$34.9M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$119.1M |
| Sale of investmentsSale Of Investment | $90.3M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$28.8M |
| Purchase of intangiblesPurchase Of Intangibles | -$2.3M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$2.3M |
| Other investing changesNet Other Investing Changes | -$4.4M |
| Financing cash flowFinancing Cash Flow | -$67.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$67.4M |
| Debt issuedIssuance Of Debt | $6.2M |
| Debt repaidRepayment Of Debt | -$220.0k |
| Net debt issuedNet Issuance Payments Of Debt | $6.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $6.2M |
| Long-term debt repaidLong Term Debt Payments | -$220.0k |
| Net long-term debt issuedNet Long Term Debt Issuance | $6.0M |
| Net common stock issuedNet Common Stock Issuance | -$75.6M |
| Common stock repurchasedCommon Stock Payments | -$75.6M |
| Share buybacksRepurchase Of Capital Stock | -$75.6M |
| Stock options exercisedProceeds From Stock Option Exercised | $2.9M |
| Other financing chargesNet Other Financing Charges | -$690.0k |
| Change in cashChanges In Cash | $18.4M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 21.0% |
| Cash at the start of the yearBeginning Cash Position | $151.8M |
| Cash at the end of the yearEnd Cash Position | $170.4M |
| Free cash flowFree Cash Flow | $119.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Amphastar Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 8.4 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read